Determinants of response to immune checkpoint inhibitors in melanoma [ 2017 - 2020 ]

Research Grant

Researchers: Prof Helen Rizos (Principal investigator) ,  Dr Alexander Menzies ,  Prof Barbara Fazekas De St Groth ,  Prof Georgina Long

Brief description Until recently, patients with melanoma were treated with single agent drugs that produced no improvement in overall survival. Today, almost 80% of patients will respond to new therapies and the 2-year survival is greater than 50%. Attention has turned to the combination of immunotherapies in order to improve patient responses. This research investigates the mechanisms of response and resistance to these therapies, in order to enhance the duration and rate of patient responses.

Funding Amount $AUD 1,047,219.91

Funding Scheme Project Grants

Notes Standard Project Grant